Testing a pig model for liver cancer treatments
Validation of the Genetically Malleable Oncopig Hepatocellular carcinoma (HCC) Model for Targeted Therapeutic Development
This study is testing a special type of pig that has been genetically modified to develop liver cancer like humans do, to help find better treatments for people with liver cancer by seeing how different genetic changes respond to targeted therapies.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sus Clinicals, INC. NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10931506 on NIH RePORTER |
What this research studies
This research aims to validate a genetically modified pig model that mimics human liver cancer, specifically hepatocellular carcinoma (HCC). By using advanced techniques like CRISPR to induce specific genetic mutations, the study will evaluate personalized therapies delivered directly to the tumor site. This approach focuses on understanding how different genetic profiles respond to targeted treatments, which could lead to more effective therapies for patients with HCC. The research is crucial as HCC is a common and aggressive cancer, highlighting the need for innovative treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hepatocellular carcinoma who may benefit from targeted therapies.
Not a fit: Patients with liver cancer types that do not share genetic similarities with the Oncopig model may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with liver cancer.
How similar studies have performed: Previous research using genetically modified animal models has shown promise in developing targeted cancer therapies, suggesting a potential for success in this approach.
Where this research is happening
Cincinnati, United States
- Sus Clinicals, INC. — Cincinnati, United States (Active)
Researchers
- Principal investigator: Schachtschneider, Kyle — Sus Clinicals, INC.
- Study coordinator: Schachtschneider, Kyle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.